Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults
SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. We compared receptor binding domain–binding antibody (RBDAb) titers and SARS-CoV-2–neutralizing antibody titers, measured by pseudovirus-neutralizing antibody assay in serum specimens obtained from children aged 0–4 years and […]
Impact of Age and Symptom Development on SARS-CoV-2 Transmission in Households With Children-Maryland, New York, and Utah, August 2020-October 2021
Households are common places for spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated factors associated with household transmission and acquisition of SARS-CoV-2. Households with children age <18 years were enrolled into prospective, longitudinal cohorts and followed from August 2020 to August 2021 in Utah, September 2020 to August 2021 in New York […]
Assessment of Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children Aged 0 to 4 Years and Their Household Members
Few studies have prospectively assessed SARS-CoV-2 community infection in children aged 0 to 4 years. Information about SARS-CoV-2 incidence and clinical and virological features in young children could help guide prevention and mitigation strategies.
The strategy of protecting young infants against RSV LRTI through delivery of RSV neutralizing antibodies is rooted in epidemiologic data demonstrating an association between neutralizing antibody titers and protection against RSV LRTI, and in the development of two products that have protected preterm infants against RSV LRTI: intravenous immunoglobulin containing high
titers of RSV-neutralizing antibodies (RSVIGIV), and an RSV F mAb (palivizumab) with potent neutralizing activity.
An essential concept in evaluating the safety of medical products is making the appropriate comparison to assess the potential risks and benefits.When compared to no vaccine, the benefits of vaccination with the Ad26.COV2.S vaccine far exceed the risks for all groups at this time. This is the key issue for much of the world, where the adenovirus-vectored vaccines are often the most (and in many cases the only) readily available option and will save many lives.
In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, […]
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children
A promising attenuation strategy involves deletion of most of the open reading frame (ORF) encoding the RNA synthesis regulatory protein M2-2. The RSV M2-2 protein is a small, nonabundant protein encoded by the second, downstream ORF in the M2 messenger RNA, which slightly overlaps the 5’ proximal, upstream M2-1 ORF
As the world rushes to develop new vaccines against Covid-19, there is a real risk that pregnant women and their babies will not be among those who are able to benefit from them.